Articles published by Cartography Biosciences, Inc.

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer

Today 7:30 EST

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

January 06, 2026

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer

December 18, 2025

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic

October 02, 2025

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team

September 03, 2025

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Unveils First Pipeline Program Targeting a Highly-Specific and Emerging Colorectal Cancer Antigen in Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

November 04, 2024

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

October 29, 2024

From Cartography Biosciences, Inc.

Via Business Wire

Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs

May 28, 2024

From Cartography Biosciences, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Cartography Biosciences, Inc.

Starting at $3.75/week.

Subscribe Today